Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)
Field | Value | Language |
dc.contributor.author | Daniels, Benjamin | |
dc.contributor.author | Girosi, Federico | |
dc.contributor.author | Tervonen, Hanna | |
dc.contributor.author | Kiely, Belinda E | |
dc.contributor.author | Lord, Sally J | |
dc.contributor.author | Houssami, Nehmat | |
dc.contributor.author | Pearson, Sallie-Anne | |
dc.date.accessioned | 2021-09-08T05:33:24Z | |
dc.date.available | 2021-09-08T05:33:24Z | |
dc.date.issued | 2018 | en_AU |
dc.identifier.uri | https://hdl.handle.net/2123/25957 | |
dc.description.abstract | Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines. As therapeutic options continue to expand, these restrictions may not be perceived to align with best practice and it is not known if their use in the real-world clinic adheres to these restrictions. We examined the treatment of women receiving trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) to determine the extent to which treatment adhered to national prescribing restrictions. | en_AU |
dc.language.iso | en | en_AU |
dc.publisher | Public Library of Science | en_AU |
dc.relation.ispartof | PLoS ONE | en_AU |
dc.rights | Creative Commons Attribution 4.0 | en_AU |
dc.subject | cancer treatment | en_AU |
dc.subject | chemotherapy | en_AU |
dc.subject | combination chemotherapy | en_AU |
dc.subject | chemotherapeutic agents | en_AU |
dc.subject | oncology | en_AU |
dc.subject | breast cancer | en_AU |
dc.subject | metastasis | en_AU |
dc.title | Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016) | en_AU |
dc.type | Article | en_AU |
dc.subject.asrc | 1112 Oncology and Carcinogenesis | en_AU |
dc.subject.asrc | 1117 Public Health and Health Services | en_AU |
dc.identifier.doi | 10.1371/journal.pone.0198152 | |
dc.relation.nhmrc | 1060407 | |
dc.relation.nhmrc | 1094325 | |
dc.relation.other | a Cancer Australia Priority Driven Collaborative Support Scheme (ID: 1050648) | |
usyd.faculty | SeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Health | en_AU |
usyd.citation.volume | 13 | en_AU |
usyd.citation.issue | 7 | en_AU |
workflow.metadata.only | No | en_AU |
Associated file/s
Associated collections